MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- IPCA LABS - ALKEM LABORATORIES
IPCA LABS vs ALKEM LABORATORIES - Comparison Results
Current Valuations
| IPCA LABS | ALKEM LABORATORIES | IPCA LABS/ ALKEM LABORATORIES |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 25.4 | 21.5 | 118.3% | View Chart |
| P/BV | x | 4.9 | 4.9 | 100.6% | View Chart |
| Dividend Yield | % | 0.4 | 1.0 | 44.1% |
Financials
 IPCA LABS  ALKEM LABORATORIES |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| IPCA LABS Mar-21 |
ALKEM LABORATORIES Mar-21 |
IPCA LABS/ ALKEM LABORATORIES |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 2,456 | 3,150 | 78.0% | |
| Low | Rs | 1,371 | 2,224 | 61.7% | |
| Sales per share (Unadj.) | Rs | 423.3 | 741.4 | 57.1% | |
| Earnings per share (Unadj.) | Rs | 90.6 | 135.3 | 66.9% | |
| Cash flow per share (Unadj.) | Rs | 107.1 | 158.3 | 67.6% | |
| Dividends per share (Unadj.) | Rs | 4.00 | 30.00 | 13.3% | |
| Avg Dividend yield | % | 0.2 | 1.1 | 18.7% | |
| Book value per share (Unadj.) | Rs | 370.6 | 616.8 | 60.1% | |
| Shares outstanding (eoy) | m | 126.85 | 119.57 | 106.1% | |
| Bonus / Rights / Conversions | 0 | 0 | - | ||
| Price / Sales ratio | x | 4.5 | 3.6 | 124.7% | |
| Avg P/E ratio | x | 21.1 | 19.9 | 106.4% | |
| P/CF ratio (eoy) | x | 17.9 | 17.0 | 105.3% | |
| Price / Book Value ratio | x | 5.2 | 4.4 | 118.5% | |
| Dividend payout | % | 4.4 | 22.2 | 19.9% | |
| Avg Mkt Cap | Rs m | 242,728 | 321,244 | 75.6% | |
| No. of employees | `000 | NA | NA | - | |
| Total wages/salary | Rs m | 10,136 | 16,210 | 62.5% | |
| Avg. sales/employee | Rs Th | 0 | 0 | - | |
| Avg. wages/employee | Rs Th | 0 | 0 | - | |
| Avg. net profit/employee | Rs Th | 0 | 0 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 53,699 | 88,650 | 60.6% | |
| Other income | Rs m | 1,292 | 2,332 | 55.4% | |
| Total revenues | Rs m | 54,991 | 90,982 | 60.4% | |
| Gross profit | Rs m | 14,812 | 19,424 | 76.3% | |
| Depreciation | Rs m | 2,092 | 2,746 | 76.2% | |
| Interest | Rs m | 123 | 589 | 20.8% | |
| Profit before tax | Rs m | 13,890 | 18,421 | 75.4% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 2,401 | 2,243 | 107.0% | |
| Profit after tax | Rs m | 11,488 | 16,178 | 71.0% | |
| Gross profit margin | % | 27.6 | 21.9 | 125.9% | |
| Effective tax rate | % | 17.3 | 12.2 | 142.0% | |
| Net profit margin | % | 21.4 | 18.2 | 117.2% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 34,370 | 69,288 | 49.6% | |
| Current liabilities | Rs m | 11,331 | 36,041 | 31.4% | |
| Net working cap to sales | % | 42.9 | 37.5 | 114.4% | |
| Current ratio | x | 3.0 | 1.9 | 157.8% | |
| Inventory Days | Days | 49 | 20 | 248.8% | |
| Debtors Days | Days | 6 | 66 | 8.3% | |
| Net fixed assets | Rs m | 26,295 | 34,825 | 75.5% | |
| Share capital | Rs m | 254 | 239 | 106.1% | |
| "Free" reserves | Rs m | 46,763 | 73,517 | 63.6% | |
| Net worth | Rs m | 47,017 | 73,756 | 63.7% | |
| Long term debt | Rs m | 365 | 343 | 106.7% | |
| Total assets | Rs m | 60,664 | 104,114 | 58.3% | |
| Interest coverage | x | 114.2 | 32.3 | 354.0% | |
| Debt to equity ratio | x | 0 | 0 | 167.4% | |
| Sales to assets ratio | x | 0.9 | 0.9 | 104.0% | |
| Return on assets | % | 19.1 | 16.1 | 118.8% | |
| Return on equity | % | 24.4 | 21.9 | 111.4% | |
| Return on capital | % | 29.6 | 25.7 | 115.3% | |
| Exports to sales | % | 0 | 22.1 | 0.0% | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | 19,555 | 0.0% | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 27,172 | 19,555 | 139.0% | |
| Fx outflow | Rs m | 7,949 | 2,467 | 322.1% | |
| Net fx | Rs m | 19,223 | 17,088 | 112.5% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 10,901 | 12,649 | 86.2% | |
| From Investments | Rs m | -5,207 | -9,985 | 52.1% | |
| From Financial Activity | Rs m | -3,058 | -2,718 | 112.5% | |
| Net Cashflow | Rs m | 2,636 | -17 | -15,326.7% | |
Share Holding
| Indian Promoters | % | 46.3 | 57.1 | 81.0% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 44.0 | 19.6 | 224.9% | |
| FIIs | % | 11.0 | 5.4 | 203.7% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 53.7 | 42.9 | 125.3% | |
| Shareholders | 115,335 | 81,869 | 140.9% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare IPCA LABS With: SUN PHARMA CIPLA LUPIN DR. REDDYS LAB ZYDUS LIFESCIENCES
Today's Market
Sensex Ends 111 Points Lower, Nifty Holds 15,750; ONGC, Reliance Crash, while ITC & Bajaj Twins Gain 4%(Closing)
After opening the day deep in the red, Indian share markets slowly recovered most of their losses and ended on a flat note.
Related Views on News
5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)
Dec 3, 2021As the new variant of Covid-19 emerges, keep an eye on these stocks.
5 Takeaways from Sun Pharma's Q4 Results (Views On News)
May 30, 2022It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.
Why Divi's Lab Share Price is Falling (Views On News)
May 24, 2022Here's why Divi's Lab's stock fell over 10% in two days.
Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)
May 23, 2022For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)
May 19, 2022During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
More Views on NewsMost Popular
Best Monopoly Stocks to Own in 2022(Views On News)
Jun 18, 2022Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.
The One Smallcap Stock I'll Recommend Now(Profit Hunter)
Jun 21, 2022This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.
Wait! Don't Buy the Smallcap 'Dip' Just Yet(Profit Hunter)
Jun 20, 2022Why this may not be the best time to buy smallcaps.
5 Consistent Compounding Stocks Available at Discount. Time to Buy?(Views On News)
Jun 22, 2022The good side of a market correction? Investors get consistent compounding stocks at a discount.
Looking for Value Stocks Amid Volatile Times? Consider These 5 Stocks(Views On News)
Jun 20, 2022These value stocks have the potential to deliver good returns in the long run. Watch out for them.
MoreOUR TOP 5 IDEAS
IPCA LABS SHARE PRICE
Jul 1, 2022 (Close)
TRACK IPCA LABS
- Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON IPCA LABS
IPCA LABS - BAJAJ HEALTHCARE COMPARISON
COMPARE IPCA LABS WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks in 2022
TRENDING TOPICS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.